Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data Read more →

SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launch Read more →

Labcorp launches new hepatitis D test to find patients with most severe form of virus Read more →